NCT05122858

Brief Summary

The main objective is to compare the EUS-BD with the insertion of a LAMS vs. traditional ERCP to restore biliary patency. Although ERCP has been the primary treatment for many years, it is associated with a significant risk of procedural complications and possible stent blockage. EUS-BD has been shown to be potentially safer and is associated with a lower risk of stent blockage. We seek with our study to determine whether EUS-BD may be the most effective treatment modality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 13, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 13, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 14, 2021

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 4, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

November 17, 2021

Completed
Last Updated

November 17, 2021

Status Verified

November 1, 2021

Enrollment Period

6 months

First QC Date

November 4, 2021

Last Update Submit

November 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of participant with stent dysfunction (obstruction or migration) requiring endoscopic, radiological or surgical intervention

    12 months

Study Arms (2)

EUS guided biliary drainage

EXPERIMENTAL
Procedure: EUS guided biliary drainage

ERCP (Endoscopic Retrograde Cholangiopancreatography

ACTIVE COMPARATOR
Procedure: ERCP

Interventions

A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.

EUS guided biliary drainage
ERCPPROCEDURE

A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.

ERCP (Endoscopic Retrograde Cholangiopancreatography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Radiological diagnosis (with or without pathological diagnosis) of a malignant obstruction of the borderline resectable distal bile ducts, locally advanced or unresectable distal to the hilum, at a minimum distance of 2 cm.
  • Resectability based on tumor staging after axial imaging and evaluation by a physician (surgeon, oncologist and / or gastroenterologist).
  • High results of the liver function test with a serum bilirubin level at least 3 times above the upper limit of normal (18.9 μmol / L)
  • Dilated extrahepatic bile duct measuring at least 1.2 cm in axial imaging, ultrasound or endoscopy.
  • Karnofsky index\> 30%
  • ASA score \<IV
  • Patient accepting the constraints of research
  • Patient affiliated or beneficiary of a social security scheme
  • Patient having signed an informed consent

You may not qualify if:

  • \- Hilar obstruction (biliary obstruction located \<2 cm from the hilum)
  • Coagulopathy and / or thrombocytopenia that cannot be corrected
  • Age \<18 years old
  • Liver metastases involving\> 30% of hepatic volume
  • Liver cirrhosis with portal hypertension or ascites
  • Biliary sphincterotomy or placement of a stent performed in the past
  • Anatomy modified by surgery
  • Common bile ducts measuring less than 1.2 cm will be excluded.
  • Patient with clinical and radiological signs of stenosis of the gastric outlet
  • Patient participating in another clinical study
  • Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
  • Pregnant, breastfeeding or parturient woman
  • Patient hospitalized without consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Privé des Peupliers

Paris, 75013, France

Location

MeSH Terms

Interventions

Cholangiopancreatography, Endoscopic Retrograde

Intervention Hierarchy (Ancestors)

CholangiographyRadiography, AbdominalRadiographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, Digestive SystemEndoscopy, Digestive SystemEndoscopyDiagnostic Techniques, SurgicalDigestive System Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical Procedures

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2021

First Posted

November 17, 2021

Study Start

November 13, 2020

Primary Completion

May 13, 2021

Study Completion

June 14, 2021

Last Updated

November 17, 2021

Record last verified: 2021-11

Locations